RI
Repositioning IntelligenceResearch Intelligence · Not for Patient Care
All targets

Target workspace

AMP-activated protein kinase

Energy sensor kinase regulating metabolism and cell growth.

Pathway & druggability

AMPK / mTOR crosstalk

Druggability: Indirectly modulated; direct agonists in development

Evidence behind this

Confidence score62%
Signal strength: LowLevel 2b–3 (observational + preclinical)
Evidence grade
Moderate Evidence

Observational studies suggest reduced cancer incidence; RCTs in adjuvant setting show mixed results.

Mechanism

AMPK activation suppresses mTOR-mediated proliferation in breast epithelial cells.

observationalmeta analysispreclinicalPhase II

Authoritative sources

  • PubMed · 22019127

    Metformin and cancer risk in diabetic patients

    Decensi A et al. (2012)

    View
  • PubMed · 23487376

    Metformin and breast cancer: a systematic review

    Coleman CB et al. (2013)

    View
  • ClinicalTrials.gov · NCT01101438

    Metformin in early breast cancer (MA.32)

    View

AI-generated summary

Generated March 15, 2026Last verified June 28, 2026

Metformin shows mechanistic plausibility and epidemiological support for breast cancer risk reduction, but prospective RCT evidence in treatment-naïve adjuvant settings remains inconclusive. Suitable for hypothesis generation and trial design, not clinical recommendation outside diabetes care.

Source papers
  • Decensi A et al., 2012
  • Coleman CB et al., 2013

This summary is AI-assisted and human-reviewed. It does not constitute medical advice. Always consult authoritative sources and qualified professionals.